Background: Neural inertia is defined as the tendency of the central nervous system to resist transitions between arousal states. This phenomenon has been observed in mice and Drosophila anaesthetized with volatile anaesthetics: the effectsite concentration required to induce anaesthesia in 50% of the population (C 50 ) was significantly higher than the effectsite concentration for 50% of the population to recover from anaesthesia. We evaluated this phenomenon in humans using propofol or sevoflurane (both with or without remifentanil) as anaesthetic agents. Methods: Thirty-six healthy volunteers received four sessions of anaesthesia with different drug combinations in a stepup/step-down design. Propofol or sevoflurane was administered with or without remifentanil. Serum concentrations of propofol and remifentanil were measured from arterial blood samples. Loss and return of responsiveness (LOR-ROR), response to pain (PAIN), Patient State Index (PSI) and spectral edge frequency (SEF) were modeled with NONMEM®. Results: For propofol, the C 50 for induction and recovery of anaesthesia was not significantly different across the different endpoints. For sevoflurane, for all endpoints except SEF, significant differences were found. For some endpoints (LOR and PAIN) the difference was significant only when sevoflurane was combined with remifentanil. Conclusions: Our results nuance earlier findings with volatile anaesthetics in mice and Drosophila. Methodological aspects of the study, such as the measured endpoint, influence the detection of neural inertia. A more thorough definition of neural inertia, with a robust methodological framework for clinical studies is required to advance our knowledge of this phenomenon. Clinical trial registration: NCT 02043938.
Keywords: anaesthesia, general; anaesthesia, inhalation; anaesthesia, intravenous; consciousness monitors; unconsciousness/drug effects Clinical observations give the impression that the relationship between hypnotic effect and hypnotic drug concentration at the effect site is different during induction and recovery of anaesthesia, resulting in a different effect-site concentration at loss (LOR) and return of responsiveness (ROR). To explain this phenomenon, Friedman and colleagues 1 introduced the concept of neural inertia, the tendency of the central nervous system to resist transitions between arousal states. They found that mice and flies, anaesthetized using steady-state titration of isoflurane or halothane, showed ROR at significantly lower volatile agent concentrations compared with the concentrations found at LOR. As a result, their concentrationeresponse curves for the recovery phase shifts to the left compared with induction. Causality of this phenomenon was suggested, including a potential role for adrenergic effects and genetic predisposition. 1 If neural inertia is an intrinsic neurophysiological entity of neurones, neural networks or brain tissue, then the accompanying difference in concentrationeresponse relationship between induction and recovery should exist for various hypnotic drugs and should be consistent across species. The aim of this four-period randomized sequence crossover study was to evaluate the animal findings on neural inertia in humans using various pharmacodynamic endpoints frequently used in clinical practice (LOReROR, response to noxious stimulation, two derived electroencephalographic indices) during stepwise increasing and decreasing pseudo steady-state concentrations of propofol or sevoflurane with or without remifentanil. For this, we developed pharmacodynamic models for each endpoint and tested if adding model parameters describing neural inertia would result in a better fit of the data. Additionally, the influence of remifentanil on neural inertia was studied.
Methods
This study was registered at Clinical Trials.gov (Identifier NCT02043938) and approved by the Institutional Review Board of the University Medical Center Groningen (NL43238.042.13). All medical devices used in this study are approved for the purposes applied in the study. They are also clinically used in our hospital and are CE labelled. All drugs and the route of administration, either alone or in combination, are approved for clinical use under the studied conditions. No 'off-label' drug applications were used based on European regulations.
Screening, inclusion, exclusion, randomization
We included, in an age-and sex-stratified way (Table 1) , 36 healthy volunteers (ASA physical status 1) with normal cognitive function. Volunteers were recruited by QPS (Groningen, The Netherlands), a certified contract research organization supporting preclinical and clinical drug development. Written informed consent was obtained from all volunteers prior to inclusion.
Exclusion criteria were weight <70% or >130% of ideal body weight, pregnancy, neurological disorder, diseases involving the cardiovascular, pulmonary, gastric, or endocrinological system, recent use of psychoactive medication, or intake of >20 g of alcohol daily. No ethnic-based criteria were applied in the selection.
The volunteers were scheduled to receive four sessions of anaesthesia with different drug combinations administered in a random order with a minimal interval of 1 week between sessions. Randomization was performed before each session by drawing a closed envelope. Any volunteer withdrawing from the study before finishing all sessions was replaced by a new recruited volunteer. The four sessions are named 'propofol alone' (Group P), 'sevoflurane alone' (Group S), 'propofol combined with remifentanil' (Group PR), and 'sevoflurane combined with remifentanil' (Group SR). During the sessions with remifentanil an effect-site concentration of 2 or 4 ng ml À1 was targeted. Inclusions were stratified according to age, sex and the targeted effect-site concentration of remifentanil (Ce REMI ). (Table 1) .
Preparation, safety procedures and airway management
The study was executed in a quiet research unit near the operating rooms of the University Medical Center Groningen Editor's key points
Neural inertia, evident in differences in anaesthetic concentration at loss and recovery of consciousness, has been demonstrated in animal models Neural inertia involving multiple endpoints was investigated in human volunteers undergoing induction and emergence from propofol or sevoflurane anaesthesia with or without co-administered remifentanil Evidence for neural inertia was found for sevoflurane, greater in the presence of remifentanil, but not for propofol that was exclusively equipped for this study. This included all mandatory monitoring, airway management tools, and personnel to guarantee safe administration of anaesthetic drugs. All volunteers fasted for at least 6 h before the start of the drug administration. No premedication was administered. The volunteer was placed in a supine position and asked to relax and close their eyes before measurements started. An anaesthetic team, consisting of an experienced nurse anaesthetist and a board-certified anaesthetist, observed the volunteer throughout the study, and were responsible for drug administration, airway, and breathing support. An additional research nurse was responsible for drawing arterial blood samples and for supervising the correct execution of the study protocol. A technician was continuously available to centrifuge and store blood samples. All observations of responsiveness to stimulation were performed by a single observer (H.N.) to avoid interobserver bias. At arrival in the research unit, a large forearm vein was cannulated using a 20G or 18G infusion catheter, and 2 ml kg À1 h À1 of crystalloid solution (Ringer Lactate, Baxter, Deerfield, IL, USA) was administered during the entire study period. The i.v. line was used for both fluids, escape medication, propofol, and remifentanil administration, if applicable. In each session requiring blood sampling, the volunteer received an arterial catheter in the radial artery under local anaesthesia (2 ml lidocaine 1%; Fresenius Kabi, Bad Homburg, Germany). The volunteers voided before onset of the study to avoid bladder distention during the procedure. After 3 h and every hour thereafter, a bladder scan (BladderScan®, BVI 3000, Verathon Inc, Bothell, WA, USA) was performed. If bladder content exceeded 500 ml, a single bladder catheterization was performed by a qualified research nurse in order to decrease the risk for a postprocedural bladder distention.
Volunteers started by breathing spontaneously through a tight-fitting face mask (Air Cushion Mask W, Medisize BV, Hillegom, The Netherlands) connected to a circular breathing system of an anaesthesia ventilator (Zeus®, Software version 4.03.35; Dr€ ager Medical, Lü beck, Germany). A sample line for end-tidal carbon dioxide, end-tidal sevoflurane (ET SEVO ) and oxygen delivery monitoring was attached to the breathing circuit. All volunteers were preoxygenated with fraction of inspired oxygen of 0.8 for 5 min. If deemed necessary, progressive steps of respiration support were applied to ensure an unobstructed airway, adequate oxygenation (SpO 2 >92%) and CO 2 (4.5e6 kPa) homeostasis throughout the study. Airway and ventilation support included: gentle chin lift or jaw trust (with or without manually assisted breathing), assisted spontaneous breathing (ASB), spontaneous intermittent mandatory volume controlled ventilation (SIMV), or positive pressure ventilation (IPPV). These standard ventilation modes were used and adapted according to the individual needs of the volunteer. After the volunteer lost responsiveness, a laryngeal mask airway (LMA Unique; Teleflex Medical, Wayne, PA, USA) was sometimes inserted to facilitate airway control at deeper levels of anaesthesia. The laryngeal mask airway was removed whenever responsiveness reoccurred, was no longer supported by the volunteer, or both. Efforts were made to minimize the intensity of noxious stimulation to the volunteer and to minimize the potential mechanical interference on the EEG monitoring systems. If a motoric, haemodynamic, or EEG response on laryngeal placement was seen the next observation phase was postponed with at least 5 min to safeguard pseudo steadystate conditions. Ventilation support was always performed by a single person (H.N.) to minimize interindividual variability in stimulus intensity. Airway manipulations were performed as much as possible outside of the pseudo steadystate observation phases.
After completion of the entire procedure, data-recording was stopped and all monitors were disconnected in order to transfer the volunteer to the recovery room until discharge criteria of the local postanaesthesia care unit were met.
Basic and study-related monitoring
All volunteers were connected to a Philips IntelliVue MP50 vital signs monitor (Philips Medizin Systeme, Boeblingen, Germany) for ECG, oxygen saturation plethysmogram, intermittently measured non-invasive blood pressure (1-min interval), and invasive arterial blood pressure (if indicated). Inspired-and end-tidal partial pressures of oxygen and carbon dioxide were monitored through the anaesthesia ventilator.
Raw EEG waveforms were measured using a frontal bilateral electrode. The electrode was attached on the forehead and connected to a Masimo Root Monitor (Model-RDS-7, Masimo, Irvine, CA, USA) that was running SEDLine® brain function software (for calculating EEG-derived indices), in concordance with the manufacturer's instructions (Masimo Inc. Anaesthetic management during the four study sessions
Each volunteer received four sessions of anaesthesia with a wash-out period of at least 1 week. The sequence was randomized to avoid carry-over effects of one session to the next. Each session contained two separate titration-phases: a stepwise up and down administration of drugs towards consecutive steady-state conditions. The sequence of events and study observations are shown in Fig 1 .
The step-up and step-down phase
After 2 min of baseline measurements, during which volunteers were asked to close their eyes and relax, a 'staircase' step-up and step-down infusion of anaesthetic drugs was administered. For group P, initial Ce PROP was set to 0.5 mg ml
À1
followed by consecutive steps toward target concentrations of 1, 1.5, 2.5, 3.5, 4.5, 6, and 7.5 mg ml À1 . For group S, initial ET SEVO was set to 0.2 vol% followed by consecutive ET SEVO values of 0.5, 1, 1.5, 2.5, 3.5, 4, and 4.5 vol%. Concentrations were increased until tolerance/no motoric response to all stimuli was reached and a significant EEG burst suppression ratio of at least 40% was observed. Next, downward staircase steps were initiated using identical targets but in reverse order. For PR and SR sessions, identical procedures were applied, albeit that 2 min before propofol or sevoflurane was started, a Ce REMI of 2 or 4 ng ml À1 was targeted and maintained throughout the study.
For more details see Online Supplement Figure 1 . Bar plots of the observed and predicted responses to a verbal command (LOR-ROR) for the different anaesthetic agents during both the step-up and step-down titration. To construct these bar plots, observations were first sorted in ascending order based on the measured propofol or sevoflurane concentration. Subsequently, observations were grouped in four or five bins and the observed probability for each bin was calculated as the proportion of volunteers who had lost/regained responsiveness. The labels on the x-axis beneath the bar plots correspond to the average measured concentration of propofol or sevoflurane in mg ml e1 or end-tidal volume %, with the upper values belonging to the step-up and the lower values belonging to the step-down bins. The number of observations within each bin is given in parentheses. ' Step-up' corresponds to the induction phase and 'step-down' to the recovery phase. The red solid curves and upward pointing triangles depict the predicted probabilities for the step-up titration, whereas a dashed curve and downward pointing triangle is used for the step-down phase.
The steps described above were applied after an interim analysis of the first eight included volunteers. These volunteers received slightly different targets: 1.5, 2, 2.5, 3, 4, 6, 8 mg ml À1 for Ce PROP and 0.5, 1, 1.5, 2, 3, 4, 5 vol% for ET SEVO . The interim analysis revealed too few responders, even after the lowest concentration target. Therefore, the protocol was amended to lower the targeted concentration. At each upwards or downwards step, an additional equilibration time of 12 min was maintained after the predicted Ce PROP or ET SEVO was reached. This approach resulted in a pharmacological pseudo-steady state. During the upwards staircase steps, whenever mean arterial pressure (MAP) was <50 mm Hg, a rescue dose of ephedrine (5 mg i.v.) was administered. If an insufficient response to the rescue medication was seen, the step-down phase was initiated before reaching the intended endpoints of tolerance to stimulation or EEG burst-suppression.
Observation of responsiveness/tolerance in pseudo steady-state At each step and after 12 min of equilibration, 1 additional min of baseline measurements in pseudo steady-state was performed. The Modified Observer's Assessment of Alertness/ Sedation (MOAA/S) scale was scored (Supplementary Table S1 ) followed by 2 min of response time (response time 1). The observed MOAA/S is used to define the endpoints LOR and ROR. LOR is defined as a transition from MOAA/S 3 (or higher) to a MOAA/S 2 (or lower). ROR is defined as a transition from MOAA/S 2 (or lower) to a MOAA/S 3(or higher). During response time 1, in session P, PR and SR a blood sample was taken via the arterial line. For remifentanil, this was done in the first three steps only as a confirmation of the steady-state in plasma concentration over time.
Two minutes after MOAA/S, an electrical stimulus was applied for maximal 30 s and tolerance/motoric responsiveness to electrical stimulation was scored, again followed by 2 min of response time (response time 2). The observed motoric response to the electrical stimulus, which could be present or absent, is used to describe the endpoint response to pain (PAIN). When MOAA/S was 5, no electrical stimulation was administered for ethical reasons, but volunteers were considered responsive to PAIN. For more details see Online Supplement Figure 2 .
The electrical stimulus was applied using the Neurometer® (Neurotron Inc, Baltimore, MD, USA), a CE-labelled clinically used device for selective nerve stimulation (primarily used for differential diagnosis of chronic polyneuropathy). It allows to give a stimulus with a fixed waveform frequency of 250 Hz, resulting in a selective stimulation of the A-d nerves, that are responsible for sharp pain sensation. 7, 8 The intensity of the electrical stimulation was adjusted according to a priori performed calibration. This calibration was performed every session, in the awake volunteer, before the study commenced.
After running the cable test as indicated by the manufacturer, the Neurometer gold sensors were connected to the right index finger, just above the fingernail. Next, repetitive electrical stimuli of 5 s were administered with 30 s intervals. After every stimulus, the intensity was increased with 0.1 mA until the volunteer started to feel some sensation at the index finger. The corresponding intensity level was recorded as the sensory perception threshold. The intensity was further adjusted using steps of 0.1 mA in a Dixon-up-and-down approach. Whenever the volunteer reported a pain-sensation with a score of 5 out of 10 on a visual analogue scale (VAS) the intensity was decreased again. This procedure was repeated until three consecutive VAS scores of 5 or higher were scored. The average intensity of the last three scores was defined as the individuals pain threshold intensity. In order to maximize the probability that the administered electrical stimulus would be sufficiently noxious to activate the nociception pathways from the finger towards the brain, we set the intensity of the stimulus to 4 mA for all volunteers, except in those that had a high individual pain threshold (higher than 2.6 mA). In these individuals, we used an intensity of 1.5-times the individual pain threshold.
Storage and analysis of blood samples
Propofol (2,6-diisopropylphenol) plasma concentrations were measured using a validated gas chromatography-mass spectrometric analysis. Lower limit of quantitation was 0.25 mg l À1 and the method was linear up to 20 mg l À1 . Coefficient of variation of the assay was <11% over the entire working range. Blood was collected in EDTA tubes, stored in a refrigerator until all samples were collected and transferred to the laboratory for centrifugation (maximally 6e8 h after blood sampling). The EDTA plasma was stored in a e80 C freezer. Remifentanil plasma concentrations were measured using a liquid chromatographyetandem mass spectrometer. 9 For remifentanil, the best sample stability was obtained by placing tubes containing EDTA whole blood in ice water immediately after sampling, followed by centrifugation (within 10 min) using a e20 C centrifuge and transfer of the EDTA plasma to tubes with the addition of 1.5 ml of formic acid per millilitre of EDTA plasma. This procedure results in a maximal remifentanil degradation of 4.2% after 19 h of storage at ambient temperature. 9 Samples were stored in a e70 C freezer for maximal stability until analysis.
Pharmacodynamic modelling
The relationship between the measured propofol plasma concentrations or ET SEVO concentrations and the pharmacodynamic measures of the anaesthetic drug effect was modelled with NONMEM® (version 7.3; Icon Development Solutions, Hanover, MD, USA). For this, a sigmoid E max model, as shown in Equation (1), was fitted to the data.
In this model, the pharmacodynamic endpoint (Effect: LOReROR, PAIN, PSI, SEF) is related to the measured concentration of propofol or sevoflurane (C) according to a nonlinear function with g defining the steepness of the concentrationeeffect relationship. In our study, equilibration times were sufficiently long such that it was assumed that steadystate was reached. Therefore, we assumed that the measured plasma concentrations for propofol and the measured ET SEVO could be used as a surrogate for their respective effect-site concentrations. E 0 is the baseline measurement of the PD endpoint when no drug is present and E max is the maximum drug effect. C 50 is the concentration that produces 50% of the maximal drug effect. Interindividual variability (IIV) was introduced by assuming a lognormal distribution of C 50 , with h i being an individual realization from this distribution with variance u. As shown in Equations (2e4), the C 50 was parameterized to allow: (i) a change in C 50 when remifentanil was added to the dosing regimen (INT); and (ii) a difference in C 50 between the induction and the recovery phase (NI).
In these models, q 1 and q 2 are zero for all volunteers not receiving remifentanil. For volunteers receiving remifentanil q 1 (2 ng ml
À1
) or q 1 and q 2 (4 ng ml
) are estimated from the data. In case a (strong) interaction between remifentanil and propofol or sevoflurane exists, the estimate for q 1 will be significantly different from zero. Moreover, if the interaction for volunteers in the 4 ng ml À1 group exceeds the estimated interaction for the 2 ng ml À1 group, q 2 will be significantly higher than zero.
The presence or absence of neural inertia was estimated from the data through parameters q 3 , q 4 , and q 5. For this, an indicator variable was added to the dataset to distinguish between the step-up and the step-down phase of the study.
During the step-down q 3 , q 4 , and q 5 were zero. For the step-up phase, these parameters were estimated from the data. More specifically, q 3 , q 4 , and q 5 estimate the increase in C 50 for the induction phase as compared with the recovery phase. Different parameters were used to distinguish the difference in C 50 s between the 0, 2, and 4 ng ml À1 remifentanil groups. q 3 quantifies the difference in C 50 between induction and recovery for the propofol and sevoflurane groups, whereas q 4 and q 5 are used to quantify this difference in the groups where 2 or 4 ng ml À1 remifentanil was used. If, for example, we would find that in the 2 ng ml À1 remifentanil þ propofol group the C 50 for the induction phase is higher than the C 50 for the recovery phase, q 4 would be significantly different from zero for this group and the estimate for q 4 would then quantify the magnitude of the difference in C 50 between the induction and the recovery phase.
Model development and parameter estimation
The first-order conditional estimation algorithm with interaction (FOCE-I) as implemented in NONMEM® was used to fit the continuous PSI and SEF data. For the LOReROR and PAIN data, the Laplacian approximation to the likelihood was used. For these endpoints E 0 and E max were fixed to 0 and 1 to a priori define a very low/high probability at low/high anaesthetic drug concentration. IIV was modelled using exponential models. Residual unexplained variability was described using additive error models. Separate models were built for the different PD endpoints. For each endpoint, we started from a full model. This full model consisted of a single PD baseline parameter (E 0 ), two sets of drug effect parameters (E max , C 50 and g), one for the propofol sessions and one for the sevoflurane sessions, two sets of interaction parameters (q 1 and q 2 ), two sets of neural inertia parameters (q 3, q 4 , and q 5 ), and five parameters describing the interindividual variability in the baseline and the C 50 s, the correlation between the C 50 s for propofol and sevoflurane (rC 50 ) and the residual error variance (s Additive 2 ). Next, this saturated model was simplified by removing non-significant parameters. An increase of the objective function value of <3.84, corresponding to a value of P<0.05, was considered non-significant and led to the removal of the tested parameter.
All models were fitted to the data using PsN 10 and Pirana 11 as back-end, front-end, or both to NONMEM®. The numerical and graphical assessment of the GOF was conducted in R® (R Foundation for Statistical Computing, Vienna, Austria). All model parameters are reported as typical values with associated relative standard errors (RSE).
Statistical analysis
Statistical significance is set at P<0.05 unless stated otherwise. All model parameters are reported as typical values (SE). Clinical data are given as mean (SD) or as median (range), as appropriate.
Results
Thirty-six volunteers concluded the study. The screening and inclusion methodology can be found in Supplementary Figure S3 . Sixteen of the 36 volunteers were male, and 20 were female. The 36 volunteers included in the analysis had a mean (range) age of 43.3 (20e70) yr, body weight of 75.3 (48e104) kg, height of 174.7 (159e197) cm and body mass index of 24.5 (19e28.9) kg m À2 .
The median duration (range) for each session was 231 (126e284), 209 (128e308), 198 (156e280) and 206 (144e298) min for propofol, propofol þ remifentanil, sevoflurane, and sevoflurane þ remifentanil, respectively.
In almost every session, the anaesthesiologisteresearcher supported spontaneous ventilation by gentle manually assisted breathing when necessary. ASB, SIMV and IPPV, or a combination of these ventilation modes were used in 103 out of 144 sessions to maintain normocapnia and to maintain an unobstructed airway.
Furthermore, a Mayo tube was inserted in 52 (36%) out of the 144 sessions.
A laryngeal mask was inserted to facilitate ventilation in 97 (67%) out of the 144 sessions. This was done 9.1 min (SD 2.1; range: 4.3e17.7 min) prior to observations (MOAA/S and PAIN).
In total, 1601 MOAA/S and 1387 PAIN observations were included in the analysis. Measured arterial propofol and remifentanil concentrations and ET SEVO concentrations were used as surrogates for their respective effect-site concentrations in the analysis. In total, 1091 arterial blood samples were drawn during induction and recovery. From these samples, 887 propofol and 204 remifentanil concentrations were measured. From the continuously measured ET SEVO , only those exactly matching the timing of the MOAA/S and PAIN observations were retained in the dataset, constituting a total of 802 measurements. All observed data included in our analysis are presented in Figs 1e4. Table 2 shows the parameter estimates for the various pharmacodynamic models. Besides the drug effect parameters (E 0 , E max , C 50 , g) for the different endpoints during propofol and sevoflurane administration, Table 2 also shows the influence of remifentanil 2 ng ml À1 (q 1 ) and 4 ng ml À1 (q 2 ) and neural inertia (q 3 , q 4 , q 5 for the 0, 2 and 4 ng ml An increase in remifentanil concentration from 2 to 4 ng ml À1 was associated with a sublinear decrease in the C 50 values for LOReROR and PAIN (a linear decrease would have q 2 equal to 1). For PSI and SEF, no differences were found in the C 50 values between the 2 and 4 ng ml À1 remifentanil groups. IIV in C 50 values was similar between propofol and sevoflurane across endpoints. Only for PAIN was a significantly (almost two-fold) higher IIV found for propofol compared with sevoflurane. Generally, the correlation between an individual's C 50 for propofol and sevoflurane was high, with correlation coefficients ranging from 0.67 (PAIN) to 0.85 (SEF). For propofol, the C 50 for the induction and recovery phase was not significantly different. Neither the addition of remifentanil to the dosing regimen nor the evaluation of a different endpoint other than LOReROR changed this conclusion. In Table 2 , this is shown as non-significant values for q 3 , q 4 , and q 5 . Bar plots of the observed and predicted responses to a noxious stimulus (PAIN) for the different anaesthetic agents during both the step-up and step-down titration. To construct these bar plots, observations were first sorted in ascending order based on the measured propofol or sevoflurane concentration. Subsequently, observations were grouped in four or five bins and the observed probability for each bin was calculated as the proportion of volunteers who had lost/regained responsiveness. The labels on the x-axis beneath the bar plots correspond to the average measured concentration of propofol or sevoflurane in mg ml À1 or end-tidal volume %, with the upper values belonging to the step-up and the lower values belonging to the step-down bins. The number of observations within each bin are given between the parentheses. ' Step-up' corresponds to the induction phase and 'step-down' to the recovery phase. The red solid curves and upward pointing triangles depict the predicted probabilities for the step-up titration whereas a dashed curve and downward pointing triangle is used for the step-down phase.
For sevoflurane, the results are less straightforward. Significant differences were observed depending on whether sevoflurane was administered alone or in combination with remifentanil and across the different evaluated endpoints. For LOReROR a difference in the C 50 s was found for sevoflurane with remifentanil. In the sevoflurane þ 2 ng ml À1 remifentanil group we found an 18% increase in the C 50 for induction vs recovery phase. Moreover, an increase in remifentanil concentration from 2 to 4 ng ml À1 led to an additional increase in C 50 of 40%. For PAIN the C 50 was significantly different between induction and recovery for the sevoflurane þ 4 ng ml À1 remifentanil group only (þ60%). The most consistent difference between induction and recovery was seen for the PSI. In the sevoflurane alone group, the C 50 for induction was 12% higher than for recovery. In addition, we found that in both remifentanil groups (2 or 4 ng ml À1 )
the difference between the C 50 s for induction and recovery was another 34% higher. Step-up' corresponds to induction phase and 'step-down' to recovery phase. The red solid curves and upward pointing triangles depict the predicted probabilities for the step-up titration whereas a dashed curve and downward pointing triangle is used for the step-down phase.
Conversely, no significant differences were found between groups when we analysed the SEF data. Overall, the model described the data well with a close agreement between observed and model predicted outcomes (Figs 1e4).
Discussion
The phenomenon of neural inertia has not been studied in detail in humans. Our investigation aimed to explore whether neural inertia that was described by Friedman and colleagues 1 in mice and Drosophila is observable in humans. We found that neural inertia is not readily observed in humans, and was found in only six out of 24 cases. Clearly, this shows that in humans the absence or presence of neural inertia depends on the drug (combination) that is used as well as the pharmacodynamic endpoint that is studied.
For sevoflurane, we found no signs of neural inertia when evaluating LOReROR. This contradicts the findings of Friedman and colleagues 1 who found that higher isoflurane or halothane concentrations were required (i.e. higher C 50 and g)
for loss of responsiveness during induction than to regain responsiveness during recovery. Apart from the analysis of the PSI data, neural inertia was not observed using sevoflurane alone. It is at not entirely clear why we observed signs of neural inertia for the PSI whilst this was absent for LOReROR, PAIN, and SEF. The latter raises questions given that both SEF and PSI are EEG-derived indices. It was previously shown that there is a potential interaction between adrenergic effects and neural inertia. Friedman and colleagues 1 showed that in genetically modified (Dbh null) mice, which are devoid of norepinephrine and epinephrine, the effects of neural inertia were more pronounced. Remifentanil is known to lower the adrenergic response in Step-up' corresponds to the induction phase and 'step-down' to the recovery phase. The red solid curves and upward pointing triangles depict the predicted probabilities for the step-up titration whereas a dashed curve and downward pointing triangle is used for the step-down phase.
humans. 12e14 Moreover, via its effects on adrenergic neurotransmission, remifentanil might play a role in the sleep-wake regulation in animals and humans. 15e17 In line with the findings of Friedman and colleagues, 1 we found that when remifentanil was co-administered with sevoflurane, signs of neural inertia appeared for three out of four endpoints. We found no signs of neural inertia for propofol. This finding was consistent across the different groups (0, 2, 4 ng ml À1 remifentanil) and pharmacodynamic endpoints. In this context, it is worthwhile mentioning that uncertainty in the estimation of drug effect parameters is very similar between the propofol and sevoflurane groups. Moreover, estimates for the interaction between remifentanil and propofol or sevoflurane are systematically more precise (i.e. lower RSE) for the propofol groups compared with the sevoflurane groups. Altogether, this shows that statistical power to detect neural inertia was similar (if not greater) in the propofol groups compared with the sevoflurane groups. Overall, our results suggest that neural inertia is of importance only when sevoflurane and remifentanil are combined and not when propofol with/without remifentanil is used. These results might be explained by different pathways and neural circuits that drive the hypnotic effects of each drug. Although both hypnotics exert their effect through modulation of GABA-A receptors, at present it is still not fully understood which pathways and neural circuits are involved.
18e20 This is even more evident for volatile anaesthetics, which are thought to have several cellular and molecular targets besides the GABA-A receptor. 20, 21 The fact that no neural inertia was found for propofol under identical conditions in which we did observe neural inertia for sevoflurane suggests that this phenomenon interacts with pathways and neural circuits associated with sevoflurane anaesthesia that are of no/little importance for propofol anaesthesia. Our analysis also shows that identifying whether or not neural inertia is present depends on the pharmacodynamic endpoint. For example, the assessment of responsiveness (LOReROR) and reaction to a noxious stimulus (PAIN) lacks nuance and generally has a limited time resolution. If neural inertia exists in humans, it is probably a subtle phenomenon, and might require a more precise measure to be detected reliably. In that respect, the different result for the two evaluated EEG-derived indices (i.e. PSI and SEF) makes sense. If indeed, in humans, neural inertia is a rather subtle phenomenon, the noise on the pharmacodynamic measure could hamper detection of this phenomenon.
A recently published study by Warnaby and colleagues 22 exemplifies this concept. After propofol was administration to 16 healthy volunteers, the authors found signs of neural inertia in the EEG-derived 'slow-wave activity saturation' parameter. Nevertheless, no signs of neural inertia were seen for LOReROR. In line with our findings, these authors showed that the detection of neural inertia depends, among other things, on the evaluated pharmacodynamic endpoint. Besides the findings related to neural inertia, our results are in strong agreement with the literature. For example, the estimated C 50 for LOReROR for propofol (1.72 mg ml À1 ; SEM: 5.4%) comes close to the estimated C 50 of 1.68 mg ml À1 reported by Schnider and colleagues. 3 Also, the effect of remifentanil on the C 50 of propofol for LOReROR is comparable with earlier published interaction studies. 23e26 The same goes for sevoflurane, where our estimated C 50 of 0.66% (SEM 6%) for LOReROR is similar to 0.65% found by Katoh and colleagues.
27 remifentanil groups, respectively. LOReROR, loss of responsiveness, defined as a transition from MOAA/S 3 (or higher) to a MOAA/S 2 (or lower), and return of responsiveness, defined as a transition from MOAA/S 2 (or lower) to a MOAA/S 3 (or higher); PAIN, the observed motoric response to the electrical stimulus, which could be present or absent; PSI, patient state index; SEF, spectral edge frequency; E 0, the baseline measurement of the PD endpoint when no drug is present; E max , the maximum drug effect; C 50 , the concentration which produces 50% of the maximal drug effect; g, the steepness/slope of the concentration effect relationship; IIV, interindividual variability, by assuming a lognormal distribution of C 50 , with h i being an individual realization from this distribution with variance u; rC 50, the correlation between the C 50 s for propofol and sevoflurane; RUV, the residual unexplained variance (s Additive   2 ). Numbers indicate parameter estimates and associated RSE (%); NS, non-significant alteration of the full model, meaning no additional influence of remifentanil on lowering the C 50 This inspires confidence in the study design and analysis and ensures that our findings, including our results on neural inertia, are generalizable beyond the scope of our study sample. One of the strengths of our study is that we used TCI administration for the i.v. anaesthetics. This ensures a rapid achievement and accurate maintenance of the plasma and corresponding effect-site concentrations. The median performance error and median absolute performance error 28 of the applied models were 8.7% and 20% for propofol and 21% and 25% for remifentanil, respectively. This shows that during the study, there was a close agreement between the targeted and achieved plasma concentrations.
One of the limitations of the study is our choice of the k e0 values, which were used to define the study design. For propofol, we based our study design on the k e0 of 0.456 min
À1
reported by Schnider and colleagues. 23 To ascertain that the concentrations were in steady-state we waited an additional 12 min after the targeted predicted effect-site concentrations were reached, which is a generally accepted method. In the step-down phase, this occasionally leads to >45 min of equilibration time. For sevoflurane, however, the k e0 is less well known and usually as such not taken into account. Therefore, in our study, again to ascertain steady-state conditions, we waited 12 min after ET SEVO concentrations reached the target. In hindsight, this led to appreciably shorter equilibration times for the sevoflurane groups than for the propofol groups. This limitation should be interpreted cautiously. On one hand, long equilibration times for the propofol groups might have masked the effects of neural inertia. Indeed, if neural inertia is a physiological phenomenon that acts in the short term, such as baroreceptor-reflexes in the haemodynamic homeostasis, then our steady-state study design might not have been appropriate for detecting neural inertia. On the other hand, a mismatch between plasma concentrations and effect-site concentrations due to insufficient equilibration times in the sevoflurane group might have confounded our results. In that case, the perceived neural inertia could be explained by a simple pharmacokinetic phenomenon.
Future research should aim to clarify the time course of neural inertia and especially the (in)dependence of this phenomenon from effect-site equilibration. Moreover, a clear description of the phenomenon, including a clinically tangible endpoint and associated experimental framework for testing the presence or absence of this phenomenon, should be developed. These requirements are pivotal to advance our insights in the mechanisms and the magnitude of neural inertia in humans.
In conclusion, our analysis shows that neural inertia is not uniformly observed in humans, and that the phenomenon might be drug (combination) specific. For propofol we found no indication of neural inertia. For sevoflurane there was evidence for neural inertia, and the addition of remifentanil increased the magnitude of the phenomenon. Our analysis also shows that methodological choices, such as the measured endpoint and study design, could have an effect on the detection of neural inertia. A more thorough definition of neural inertia accompanied by a methodological framework for studying this phenomenon in clinical practice is necessary to advance our insights into this complex neurophysiological phenomenon.
